NCT01834248View on ClinicalTrials.gov

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 30, 2013

Primary Completion Date

June 9, 2015

Study Completion Date

March 21, 2016

Conditions
Acute Myeloid LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRefractory Anemia With Excess Blasts in Transformation
Interventions
BIOLOGICAL

DEC-205/NY-ESO-1 Fusion Protein CDX-1401

Given SC and ID

DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Poly ICLC

Given SC

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT01834248 - DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter